Direct Plan · Growth · Index Funds · Scheme code 150930
NAV₹20.9107as on 25 Sep 2026
Fund houseICICI Prudential Mutual Fund
CategoryIndex Funds
Plan & optionDirect · Growth
History3.8 years
Returns (%)
1M
3M
6M
1Y
3Y
5Y
7Y
10Y
Launch
This scheme
-0.77
8.42
15.66
17.57
18.85
—
—
—
20.86
Nifty 100 benchmark
0.25
3.49
-1.52
1.84
10.52
9.38
—
—
12.79
Index Funds category median
—
—
—
5.71
7.60
9.78
—
11.29
—
Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
14.2%
0.87
1.30
0.72
14.05%
-16.6%
38.28
Nifty 100 benchmark
17.1%
0.23
0.32
—
—
-37.0%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
44 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
135
-5.5%
15.3%
59.9%
10%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
123%
54%
0.62
13.1%
0.99
23.36
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 44 months this scheme and
Nifty 100 share.
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · Growth
Allocation
By asset
Equity
99.93%
Cash & Equivalents
0.07%
By market cap
Large Cap
47.81%
Mid Cap
45.01%
Small Cap
7.11%
Concentration
Number of stocks
20
Top 5 stocks
55.17%
Top 10 stocks
78.83%
Top 20 stocks
99.93%
Lines in the filing
22
Largest holding
20.76%
Largest sector
Pharmaceuticals & Biotechnology 99.93%
Effective stocks
11.0
Sectors held
1
Cash
0.07%
Effective stocks is what the concentration works out to: a fund holding
20 names but most of its money in a few
behaves like a fund of 11. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
99.93%
Cash & Equivalents
0.07%
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · Growth · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Sun Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
164,106
33
20.76%
2
Divi's Laboratories Ltd.
Pharmaceuticals & Biotechnology
19,688
19
11.88%
3
Cipla Ltd.
Pharmaceuticals & Biotechnology
87,200
12
7.83%
4
Laurus Labs Ltd.
Pharmaceuticals & Biotechnology
60,292
12
7.36%
5
Torrent Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
22,724
12
7.34%
6
Dr. Reddy's Laboratories Ltd.
Pharmaceuticals & Biotechnology
94,471
11
6.95%
7
Lupin Ltd.
Pharmaceuticals & Biotechnology
37,631
8
5.25%
8
Aurobindo Pharma Ltd.
Pharmaceuticals & Biotechnology
42,891
7
4.69%
9
Glenmark Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
23,325
6
3.69%
10
Alkem Laboratories Ltd.
Pharmaceuticals & Biotechnology
9,056
5
3.08%
11
Biocon Ltd.
Pharmaceuticals & Biotechnology
110,570
5
2.90%
12
Zydus Lifesciences Ltd.
Pharmaceuticals & Biotechnology
38,768
5
2.87%
13
IPCA Laboratories Ltd.
Pharmaceuticals & Biotechnology
21,518
4
2.71%
14
Mankind Pharma Ltd.
Pharmaceuticals & Biotechnology
17,534
4
2.70%
15
Gland Pharma Ltd.
Pharmaceuticals & Biotechnology
12,341
4
2.27%
16
Sai Life Sciences Ltd.
Pharmaceuticals & Biotechnology
21,374
3
1.99%
17
Wockhardt Ltd.
Pharmaceuticals & Biotechnology
12,788
2
1.54%
18
Ajanta Pharma Ltd.
Pharmaceuticals & Biotechnology
6,516
2
1.50%
19
Piramal Pharma Ltd.
Pharmaceuticals & Biotechnology
96,391
2
1.32%
20
Abbott India Ltd.
Pharmaceuticals & Biotechnology
795
2
1.31%
21
TREPS
Unclassified
—
2
1.07%
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · Growth · where the money sits
What the manager did last month
Between the filings of 31 Jul 2026 and 31 Aug 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹5 cr
₹0 cr
0
0
+3.03%
Stock
Shares traded
Shares
Price
Value ₹ cr
Added to
Sun Pharmaceutical Industries Ltd.
5,542
+3.5%
-0.3%
1.1
Divi's Laboratories Ltd.
661
+3.5%
+17.5%
0.6
Cipla Ltd.
2,941
+3.5%
-4.3%
0.4
Laurus Labs Ltd.
2,031
+3.5%
+5.4%
0.4
Torrent Pharmaceuticals Ltd.
762
+3.5%
-1.1%
0.4
Dr. Reddy's Laboratories Ltd.
3,189
+3.5%
+0.6%
0.4
Lupin Ltd.
1,267
+3.5%
-9.4%
0.3
Aurobindo Pharma Ltd.
1,444
+3.5%
+8.7%
0.3
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 26 Sep 2026.
